Marksans Pharma Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Marksans Pharma kazanç ve gelirin sırasıyla yıllık 18.6% ve 12% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 18.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

18.6%

Kazanç büyüme oranı

18.66%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	15.9%
Gelir büyüme oranı	12.0%
Gelecekteki özkaynak getirisi	15.32%
Analist kapsamı	Low
Son güncelleme	17 Nov 2025

Gelecekteki son büyüme güncellemeleri

Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

Nov 17

₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

May 22

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 15

Recent updates

Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

Dec 09

Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

Nov 17

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today

Oct 15

Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year

Aug 15

Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares

Aug 07

Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)

Jun 28

We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings

May 27

₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

May 22

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 15

Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 01

Teva Pharma Facility And US Expansion To Strengthen Future Outlook

Jan 28 Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Nov 27

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16

Kazanç ve Gelir Büyüme Tahminleri

NSEI:MARKSANS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2028	36,375	5,555	4,214	5,029	3
3/31/2027	32,046	4,689	3,325	4,368	3
3/31/2026	28,112	3,876	3,486	4,284	3
9/30/2025	27,307	3,517	346	2,047	N/A
6/30/2025	26,522	3,501	N/A	N/A	N/A
3/31/2025	26,228	3,806	337	2,067	N/A
12/31/2024	24,744	3,683	N/A	N/A	N/A
9/30/2024	23,787	3,470	520	2,169	N/A
6/30/2024	22,680	3,338	N/A	N/A	N/A
3/31/2024	21,774	3,137	216	2,304	N/A
12/31/2023	21,034	3,164	N/A	N/A	N/A
9/30/2023	19,971	2,965	894	2,528	N/A
6/30/2023	19,184	2,743	N/A	N/A	N/A
3/31/2023	18,521	2,663	1,838	2,374	N/A
12/31/2022	17,842	2,123	N/A	N/A	N/A
9/30/2022	16,670	2,004	972	1,286	N/A
6/30/2022	15,756	1,847	N/A	N/A	N/A
3/31/2022	14,908	1,868	529	993	N/A
12/31/2021	14,069	2,367	N/A	N/A	N/A
9/30/2021	14,026	2,473	883	1,336	N/A
6/30/2021	14,064	2,518	N/A	N/A	N/A
3/31/2021	13,762	2,385	1,322	1,786	N/A
12/31/2020	13,817	2,018	N/A	N/A	N/A
9/30/2020	13,142	1,724	1,839	2,478	N/A
6/30/2020	12,203	1,476	N/A	N/A	N/A
3/31/2020	11,344	1,208	1,734	2,333	N/A
12/31/2019	10,463	879	N/A	N/A	N/A
9/30/2019	9,972	834	66	416	N/A
6/30/2019	10,099	780	N/A	N/A	N/A
3/31/2019	10,001	804	N/A	274	N/A
12/31/2018	9,523	666	N/A	N/A	N/A
9/30/2018	9,223	582	N/A	N/A	N/A
6/30/2018	9,272	463	N/A	N/A	N/A
3/31/2018	9,127	358	N/A	501	N/A
12/31/2017	8,918	343	N/A	N/A	N/A
9/30/2017	8,949	275	N/A	N/A	N/A
6/30/2017	8,015	187	N/A	N/A	N/A
3/31/2017	7,672	113	N/A	141	N/A
12/31/2016	7,926	70	N/A	N/A	N/A
9/30/2016	7,948	136	N/A	N/A	N/A
6/30/2016	8,699	481	N/A	N/A	N/A
3/31/2016	8,933	785	N/A	308	N/A
12/31/2015	8,536	1,093	N/A	N/A	N/A
9/30/2015	8,495	1,191	N/A	N/A	N/A
6/30/2015	8,045	1,154	N/A	N/A	N/A
3/31/2015	7,967	1,094	N/A	1,545	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MARKSANS 'nin tahmini kazanç büyümesi (yıllık 18.6% ) tasarruf oranının ( 6.8% ) üzerindedir.

Kazançlar ve Piyasa: MARKSANS şirketinin kazançlarının (yıllık 18.6% ) Indian pazarından (yıllık 16.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: MARKSANS şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: MARKSANS şirketinin gelirinin (yıllık 12% ) Indian pazarından (yıllık 10.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MARKSANS şirketinin gelirinin (yıllık 12% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MARKSANS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.3 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/01/08 15:56
Gün Sonu Hisse Fiyatı	2026/01/08 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2025/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Marksans Pharma Limited 5 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ranjit Kapadia	Centrum Broking Limited
Deepika Murarka	Choice Equity Broking Private Limited
Maitri Sheth	Choice Equity Broking Private Limited

Marksans Pharma Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

Consensus revenue estimates fall by 10%

₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Price target increased by 26% to ₹330

Recent updates

Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

Second quarter 2026 earnings released: EPS: ₹2.17 (vs ₹2.13 in 2Q 2025)

Now 21% undervalued after recent price drop

Marksans Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today

Consensus revenue estimates fall by 10%

Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year

Now 28% undervalued after recent price drop

Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares

Upcoming dividend of ₹0.80 per share

Marksans Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025

Full year 2025 earnings: Revenues and EPS in line with analyst expectations

Marksans Pharma Limited announces Annual dividend, payable on September 07, 2025

Marksans Pharma Limited, Annual General Meeting, Aug 08, 2025

Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)

We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings

₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

Full year 2025 earnings: Revenues and EPS in line with analyst expectations

Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?

Marksans Pharma Limited to Report Q4, 2025 Results on May 19, 2025

Now 25% overvalued

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Now 24% overvalued

Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Third quarter 2025 earnings released: EPS: ₹2.31 (vs ₹1.84 in 3Q 2024)

Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value

Now 25% overvalued

Teva Pharma Facility And US Expansion To Strengthen Future Outlook

Marksans Pharma Limited to Report Nine Months, 2025 Results on Feb 11, 2025

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Marksans Pharma Limited Receives USFDA Approval for Loratadine Tablets USP 10 mg

Price target increased by 26% to ₹330

Second quarter 2025 earnings released: EPS: ₹2.13 (vs ₹1.84 in 2Q 2024)

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Marksans Pharma Limited to Report Q2, 2025 Results on Nov 12, 2024

Marksans Pharma Limited Approves Dividend for the Year Ended March 31, 2024

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Upcoming dividend of ₹0.60 per share

Insufficient new directors

Now 21% overvalued after recent price rise

Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 20% overvalued after recent price rise

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Investor sentiment improves as stock rises 18%

Whole-time Director recently bought ₹6.9m worth of stock

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Full year 2024 earnings: EPS misses analyst expectations

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023